A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-08

AUTHORS

Arun A. Azad, Emma K. Beardsley, Sebastian J. Hotte, Susan L. Ellard, Lawrence Klotz, Joseph Chin, Christian Kollmannsberger, Som D. Mukherjee, Kim N. Chi

ABSTRACT

PURPOSE: To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen deprivation therapy, minimal symptoms and were chemotherapy-naïve. Protocol therapy was either vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A) or bicalutamide 50 mg oral daily alone (Arm B) with cross-over to vandetanib monotherapy at progression. The primary endpoint was PSA response (≥ 50 % decline from baseline). RESULTS: Thirty-nine patients were recruited, 19 in Arm A and 20 in Arm B. PSA response was comparable in Arm A and Arm B (18 vs. 19 %). Time to PSA progression was 3.16 months (95 % confidence interval (CI): 1.09, not reached (NR)) for Arm A and 3.09 months (95 % CI: 1.22, NR) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B (42 vs. 5 %; p = 0.019). Treatment with vandetanib was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels. CONCLUSION: The combination of vandetanib and bicalutamide was associated with considerable toxicity and did not have superior efficacy over bicalutamide alone. Further evaluation of this combination is not warranted in mCRPC. More... »

PAGES

746-752

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8

DOI

http://dx.doi.org/10.1007/s10637-014-0091-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008660056

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24671507


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms, Castration-Resistant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tosyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Endothelial Growth Factor A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Endothelial Growth Factor Receptor-2", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Azad", 
        "givenName": "Arun A.", 
        "id": "sg:person.0716150242.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716150242.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beardsley", 
        "givenName": "Emma K.", 
        "id": "sg:person.0672204513.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672204513.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Juravinski Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.477522.1", 
          "name": [
            "Juravinski Cancer Centre, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hotte", 
        "givenName": "Sebastian J.", 
        "id": "sg:person.0660714273.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660714273.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Centre for the Southern Interior, Kelowna, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ellard", 
        "givenName": "Susan L.", 
        "id": "sg:person.01004224136.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sunnybrook Health Science Centre", 
          "id": "https://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Sunnybrook Health Sciences Centre, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klotz", 
        "givenName": "Lawrence", 
        "id": "sg:person.010764321372.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010764321372.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "London Health Sciences Centre", 
          "id": "https://www.grid.ac/institutes/grid.412745.1", 
          "name": [
            "London Health Sciences Centre, London, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chin", 
        "givenName": "Joseph", 
        "id": "sg:person.01225732325.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225732325.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kollmannsberger", 
        "givenName": "Christian", 
        "id": "sg:person.0660645031.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Juravinski Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.477522.1", 
          "name": [
            "Juravinski Cancer Centre, Hamilton, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mukherjee", 
        "givenName": "Som D.", 
        "id": "sg:person.01237110113.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237110113.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BC Cancer Agency", 
          "id": "https://www.grid.ac/institutes/grid.248762.d", 
          "name": [
            "British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada", 
            "Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Kim N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2010.28.5981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000100366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.35.5040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007010954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.0494", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013364059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.1709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014560769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1476-4598-12-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016568960", 
          "https://doi.org/10.1186/1476-4598-12-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-2353", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019084394"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0090-4295(01)01010-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019718764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005392-200102000-00095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019723635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00005392-200102000-00095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019723635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urolonc.2010.09.018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025524434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.39.4767", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031092562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31818b946b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032193378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31818b946b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032193378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e31818b946b", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032193378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1895", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033284252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdm554", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035066248"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.02.2574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035170611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(13)70184-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037354085"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)64039-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041774655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.20917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042434637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.20917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042434637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.20917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042434637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.20917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042434637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clgc.2011.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044121834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m802392200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047823885"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cbr.2008.0588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059242943"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074795197", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075104066", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075108930", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075208258", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082397609", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.8.2928", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083129509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347110", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.4515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083947895"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-08", 
    "datePublishedReg": "2014-08-01", 
    "description": "PURPOSE: To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).\nMETHODS: This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen deprivation therapy, minimal symptoms and were chemotherapy-na\u00efve. Protocol therapy was either vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A) or bicalutamide 50 mg oral daily alone (Arm B) with cross-over to vandetanib monotherapy at progression. The primary endpoint was PSA response (\u2265 50 % decline from baseline).\nRESULTS: Thirty-nine patients were recruited, 19 in Arm A and 20 in Arm B. PSA response was comparable in Arm A and Arm B (18 vs. 19 %). Time to PSA progression was 3.16 months (95 % confidence interval (CI): 1.09, not reached (NR)) for Arm A and 3.09 months (95 % CI: 1.22, NR) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B (42 vs. 5 %; p\u2009=\u20090.019). Treatment with vandetanib was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels.\nCONCLUSION: The combination of vandetanib and bicalutamide was associated with considerable toxicity and did not have superior efficacy over bicalutamide alone. Further evaluation of this combination is not warranted in mCRPC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-014-0091-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "name": "A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy na\u00efve castration-resistant prostate cancer", 
    "pagination": "746-752", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "29422a0bc6c42fbdb28138708ee4184e2fb4fdfaa79895e2ddb9e62d7dc92f8d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24671507"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-014-0091-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008660056"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-014-0091-8", 
      "https://app.dimensions.ai/details/publication/pub.1008660056"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:20", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000510.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10637-014-0091-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-014-0091-8'


 

This table displays all metadata directly associated to this object as RDF triples.

275 TRIPLES      21 PREDICATES      72 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-014-0091-8 schema:about N09d35156e55e43e1b520fe4b259b6796
2 N0b545168b5014d1e829f8030d99d2fd8
3 N0edbcb15ed4440b9a3adbb935063c7a7
4 N2833a1e31b044373b27774c3886d7a51
5 N34c49afe39504cdfb26f9fe7518b5726
6 N3878ae3b0ffd4ea286784fb757175c8a
7 N39b47768e05144d293c8e445816d0929
8 N42507373d2cd48738a6c9c186f367bab
9 N4be75178e74842908a0336af0e8fadcd
10 N736205f6526d4efa85e563ed4393bc47
11 N74288d465338448eb9eff755f2e43f60
12 Ne2d5194b06984cf2a673a694c97d536a
13 Ne5106c86d3bb4921966fb5bacfe5f969
14 Ne8e13b9578f74040a0b8afa39aa879b2
15 Nf444457aca454f888ae19b4b40c541ce
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N24dcbd6f65204ba8a4bc9aa2c653811c
19 schema:citation sg:pub.10.1186/1476-4598-12-7
20 https://app.dimensions.ai/details/publication/pub.1074795197
21 https://app.dimensions.ai/details/publication/pub.1075104066
22 https://app.dimensions.ai/details/publication/pub.1075108930
23 https://app.dimensions.ai/details/publication/pub.1075208258
24 https://app.dimensions.ai/details/publication/pub.1082397609
25 https://app.dimensions.ai/details/publication/pub.1083347110
26 https://doi.org/10.1002/ijc.20917
27 https://doi.org/10.1016/j.clgc.2011.11.003
28 https://doi.org/10.1016/j.urolonc.2010.09.018
29 https://doi.org/10.1016/s0022-5347(01)64039-4
30 https://doi.org/10.1016/s0090-4295(01)01010-x
31 https://doi.org/10.1016/s1470-2045(13)70184-0
32 https://doi.org/10.1074/jbc.m802392200
33 https://doi.org/10.1089/cbr.2008.0588
34 https://doi.org/10.1093/annonc/mdm554
35 https://doi.org/10.1097/00005392-200102000-00095
36 https://doi.org/10.1097/coc.0b013e31818b946b
37 https://doi.org/10.1158/1078-0432.ccr-06-1895
38 https://doi.org/10.1158/1078-0432.ccr-12-2353
39 https://doi.org/10.1200/jco.1997.15.8.2928
40 https://doi.org/10.1200/jco.2005.02.2574
41 https://doi.org/10.1200/jco.2010.28.5981
42 https://doi.org/10.1200/jco.2011.29.15_suppl.4515
43 https://doi.org/10.1200/jco.2011.35.5040
44 https://doi.org/10.1200/jco.2011.36.1709
45 https://doi.org/10.1200/jco.2011.39.4767
46 https://doi.org/10.1200/jco.2012.45.0494
47 schema:datePublished 2014-08
48 schema:datePublishedReg 2014-08-01
49 schema:description PURPOSE: To investigate the efficacy and safety of combining vandetanib, an orally available multi-targeted tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR), with bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: This was an open-label, randomized phase II multi-center study. Eligible patients had rising PSA on androgen deprivation therapy, minimal symptoms and were chemotherapy-naïve. Protocol therapy was either vandetanib 300 mg oral daily plus bicalutamide 50 mg oral daily (Arm A) or bicalutamide 50 mg oral daily alone (Arm B) with cross-over to vandetanib monotherapy at progression. The primary endpoint was PSA response (≥ 50 % decline from baseline). RESULTS: Thirty-nine patients were recruited, 19 in Arm A and 20 in Arm B. PSA response was comparable in Arm A and Arm B (18 vs. 19 %). Time to PSA progression was 3.16 months (95 % confidence interval (CI): 1.09, not reached (NR)) for Arm A and 3.09 months (95 % CI: 1.22, NR) for Arm B. Treatment discontinuation due to adverse events was more common in Arm A compared to Arm B (42 vs. 5 %; p = 0.019). Treatment with vandetanib was associated with a reduction in soluble VEGFR-2 levels after two cycles but an increase in plasma VEGF levels. CONCLUSION: The combination of vandetanib and bicalutamide was associated with considerable toxicity and did not have superior efficacy over bicalutamide alone. Further evaluation of this combination is not warranted in mCRPC.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N04f2ea85d367498cbe8d51625134f48a
54 N6b2bbad8e2304b158c38b8a020cbbbe2
55 sg:journal.1094201
56 schema:name A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer
57 schema:pagination 746-752
58 schema:productId N066095d356314d0fa73fd820619e300f
59 N07057caad0df480888d5c09e588eb68e
60 N37eeb205a907435992741a74f4751138
61 N4612aa4b51be4751893e13e83ff8fe2c
62 N94492bef65a64020890b173370b03ea1
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008660056
64 https://doi.org/10.1007/s10637-014-0091-8
65 schema:sdDatePublished 2019-04-10T18:20
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher Nd7ac7f8c75634e4396936bd19103269c
68 schema:url http://link.springer.com/10.1007%2Fs10637-014-0091-8
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N04f2ea85d367498cbe8d51625134f48a schema:issueNumber 4
73 rdf:type schema:PublicationIssue
74 N0614c01a223541d9b0dff4e54fd927c7 rdf:first sg:person.010764321372.53
75 rdf:rest Nf892cde4795e4c369e7a2420fffba977
76 N066095d356314d0fa73fd820619e300f schema:name readcube_id
77 schema:value 29422a0bc6c42fbdb28138708ee4184e2fb4fdfaa79895e2ddb9e62d7dc92f8d
78 rdf:type schema:PropertyValue
79 N07057caad0df480888d5c09e588eb68e schema:name nlm_unique_id
80 schema:value 8309330
81 rdf:type schema:PropertyValue
82 N09d35156e55e43e1b520fe4b259b6796 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Anilides
84 rdf:type schema:DefinedTerm
85 N0b545168b5014d1e829f8030d99d2fd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Vascular Endothelial Growth Factor A
87 rdf:type schema:DefinedTerm
88 N0edbcb15ed4440b9a3adbb935063c7a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 N24dcbd6f65204ba8a4bc9aa2c653811c rdf:first sg:person.0716150242.71
92 rdf:rest N4b8e30e7f08c42a69ee6248f903b07e3
93 N2833a1e31b044373b27774c3886d7a51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Vascular Endothelial Growth Factor Receptor-2
95 rdf:type schema:DefinedTerm
96 N34c49afe39504cdfb26f9fe7518b5726 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Antineoplastic Agents
98 rdf:type schema:DefinedTerm
99 N37eeb205a907435992741a74f4751138 schema:name dimensions_id
100 schema:value pub.1008660056
101 rdf:type schema:PropertyValue
102 N3878ae3b0ffd4ea286784fb757175c8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Aged
104 rdf:type schema:DefinedTerm
105 N39b47768e05144d293c8e445816d0929 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antineoplastic Combined Chemotherapy Protocols
107 rdf:type schema:DefinedTerm
108 N42507373d2cd48738a6c9c186f367bab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Protein Kinase Inhibitors
110 rdf:type schema:DefinedTerm
111 N4612aa4b51be4751893e13e83ff8fe2c schema:name doi
112 schema:value 10.1007/s10637-014-0091-8
113 rdf:type schema:PropertyValue
114 N4b8e30e7f08c42a69ee6248f903b07e3 rdf:first sg:person.0672204513.24
115 rdf:rest N6f7ba354dd824df7813e2f4e8cad4c28
116 N4be75178e74842908a0336af0e8fadcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prostatic Neoplasms, Castration-Resistant
118 rdf:type schema:DefinedTerm
119 N6b2bbad8e2304b158c38b8a020cbbbe2 schema:volumeNumber 32
120 rdf:type schema:PublicationVolume
121 N6f7ba354dd824df7813e2f4e8cad4c28 rdf:first sg:person.0660714273.18
122 rdf:rest Ncd28a4f0d8874d85a55814a5f6673d7b
123 N736205f6526d4efa85e563ed4393bc47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Nitriles
125 rdf:type schema:DefinedTerm
126 N74288d465338448eb9eff755f2e43f60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Tosyl Compounds
128 rdf:type schema:DefinedTerm
129 N94492bef65a64020890b173370b03ea1 schema:name pubmed_id
130 schema:value 24671507
131 rdf:type schema:PropertyValue
132 Nae08b70fcd57420b9e3825b733737bc8 rdf:first sg:person.0660645031.33
133 rdf:rest Nf256492f27524e228a30a618c0f0cde6
134 Ncd28a4f0d8874d85a55814a5f6673d7b rdf:first sg:person.01004224136.10
135 rdf:rest N0614c01a223541d9b0dff4e54fd927c7
136 Nd7ac7f8c75634e4396936bd19103269c schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 Ne2d5194b06984cf2a673a694c97d536a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Piperidines
140 rdf:type schema:DefinedTerm
141 Ne3e4efdb5024400fb36f3209bccf9882 rdf:first sg:person.01142252161.65
142 rdf:rest rdf:nil
143 Ne5106c86d3bb4921966fb5bacfe5f969 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Prostate-Specific Antigen
145 rdf:type schema:DefinedTerm
146 Ne8e13b9578f74040a0b8afa39aa879b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Quinazolines
148 rdf:type schema:DefinedTerm
149 Nf256492f27524e228a30a618c0f0cde6 rdf:first sg:person.01237110113.33
150 rdf:rest Ne3e4efdb5024400fb36f3209bccf9882
151 Nf444457aca454f888ae19b4b40c541ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Male
153 rdf:type schema:DefinedTerm
154 Nf892cde4795e4c369e7a2420fffba977 rdf:first sg:person.01225732325.58
155 rdf:rest Nae08b70fcd57420b9e3825b733737bc8
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
160 schema:name Oncology and Carcinogenesis
161 rdf:type schema:DefinedTerm
162 sg:journal.1094201 schema:issn 0167-6997
163 1573-0646
164 schema:name Investigational New Drugs
165 rdf:type schema:Periodical
166 sg:person.01004224136.10 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
167 schema:familyName Ellard
168 schema:givenName Susan L.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004224136.10
170 rdf:type schema:Person
171 sg:person.010764321372.53 schema:affiliation https://www.grid.ac/institutes/grid.413104.3
172 schema:familyName Klotz
173 schema:givenName Lawrence
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010764321372.53
175 rdf:type schema:Person
176 sg:person.01142252161.65 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
177 schema:familyName Chi
178 schema:givenName Kim N.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
180 rdf:type schema:Person
181 sg:person.01225732325.58 schema:affiliation https://www.grid.ac/institutes/grid.412745.1
182 schema:familyName Chin
183 schema:givenName Joseph
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225732325.58
185 rdf:type schema:Person
186 sg:person.01237110113.33 schema:affiliation https://www.grid.ac/institutes/grid.477522.1
187 schema:familyName Mukherjee
188 schema:givenName Som D.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237110113.33
190 rdf:type schema:Person
191 sg:person.0660645031.33 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
192 schema:familyName Kollmannsberger
193 schema:givenName Christian
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660645031.33
195 rdf:type schema:Person
196 sg:person.0660714273.18 schema:affiliation https://www.grid.ac/institutes/grid.477522.1
197 schema:familyName Hotte
198 schema:givenName Sebastian J.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660714273.18
200 rdf:type schema:Person
201 sg:person.0672204513.24 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
202 schema:familyName Beardsley
203 schema:givenName Emma K.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672204513.24
205 rdf:type schema:Person
206 sg:person.0716150242.71 schema:affiliation https://www.grid.ac/institutes/grid.248762.d
207 schema:familyName Azad
208 schema:givenName Arun A.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716150242.71
210 rdf:type schema:Person
211 sg:pub.10.1186/1476-4598-12-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016568960
212 https://doi.org/10.1186/1476-4598-12-7
213 rdf:type schema:CreativeWork
214 https://app.dimensions.ai/details/publication/pub.1074795197 schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1075104066 schema:CreativeWork
216 https://app.dimensions.ai/details/publication/pub.1075108930 schema:CreativeWork
217 https://app.dimensions.ai/details/publication/pub.1075208258 schema:CreativeWork
218 https://app.dimensions.ai/details/publication/pub.1082397609 schema:CreativeWork
219 https://app.dimensions.ai/details/publication/pub.1083347110 schema:CreativeWork
220 https://doi.org/10.1002/ijc.20917 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042434637
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/j.clgc.2011.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044121834
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/j.urolonc.2010.09.018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025524434
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/s0022-5347(01)64039-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041774655
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/s0090-4295(01)01010-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019718764
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1016/s1470-2045(13)70184-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037354085
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1074/jbc.m802392200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047823885
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1089/cbr.2008.0588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059242943
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1093/annonc/mdm554 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035066248
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1097/00005392-200102000-00095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019723635
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1097/coc.0b013e31818b946b schema:sameAs https://app.dimensions.ai/details/publication/pub.1032193378
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1158/1078-0432.ccr-06-1895 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033284252
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1158/1078-0432.ccr-12-2353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019084394
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.1997.15.8.2928 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083129509
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2005.02.2574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035170611
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2010.28.5981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000100366
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2011.29.15_suppl.4515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083947895
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2011.35.5040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007010954
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1200/jco.2011.36.1709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014560769
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1200/jco.2011.39.4767 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031092562
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1200/jco.2012.45.0494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013364059
261 rdf:type schema:CreativeWork
262 https://www.grid.ac/institutes/grid.248762.d schema:alternateName BC Cancer Agency
263 schema:name British Columbia Cancer Agency, Centre for the Southern Interior, Kelowna, BC, Canada
264 British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada
265 Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, V5Z 4E6, Vancouver, BC, Canada
266 rdf:type schema:Organization
267 https://www.grid.ac/institutes/grid.412745.1 schema:alternateName London Health Sciences Centre
268 schema:name London Health Sciences Centre, London, ON, Canada
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.413104.3 schema:alternateName Sunnybrook Health Science Centre
271 schema:name Sunnybrook Health Sciences Centre, Toronto, ON, Canada
272 rdf:type schema:Organization
273 https://www.grid.ac/institutes/grid.477522.1 schema:alternateName Juravinski Cancer Centre
274 schema:name Juravinski Cancer Centre, Hamilton, ON, Canada
275 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...